<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02014506</url>
  </required_header>
  <id_info>
    <org_study_id>AMCPHO-SCT1303</org_study_id>
    <nct_id>NCT02014506</nct_id>
  </id_info>
  <brief_title>Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents</brief_title>
  <official_title>Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of study: This phase I/II trial is to evaluate the safety and feasibility of
      TCRαβ-depleted graft from haploidentical family donors in treating children and adolescents
      with malignant or non-malignant diseases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate tralsplant-related mortality after haploidentical hematopoietic stem cell transplantation using TCRαβ-depleted graft</measure>
    <time_frame>1 year posttransplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess engraftment and graft failure</measure>
    <time_frame>28 days posttransplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the risk of acute GVHD</measure>
    <time_frame>100 days posttransplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the incidence of relapse</measure>
    <time_frame>100 days and 1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the incidence and severity of chronic GVHD</measure>
    <time_frame>1 year posttransplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the overall survival</measure>
    <time_frame>1 year posttransplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the incidence of bacterial, fungal and viral infection</measure>
    <time_frame>100 days and 1 year posttransplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the reactivation rate of CMV, EBV</measure>
    <time_frame>100 days and 1 year posttransplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immune reconstitution of T, B, and NK cells</measure>
    <time_frame>days 7, 14, 21, 28, 60, 90, 180, 270, and 365 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the lineage-specific chimerism using flow cytomery of CD3+, CD19, CD56, TCR αβ, and TCRγδ at pre-transplant</measure>
    <time_frame>days 7, 10, 14, 21, 28, 60, 90, 180, 270 and 365 post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess event free survival</measure>
    <time_frame>1 year posttransplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Haploidentical Hematopoietic Stem Cell Transplantation</condition>
  <condition>Malignant Disease</condition>
  <condition>Non-malignant Disease</condition>
  <arm_group>
    <arm_group_label>HAPLO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>40mg/M2 once daily IV on days -7 to -2</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>50 mg/kg IV on day -3 and -2</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Beginning on day 4 and continuing until blood counts recover</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 &amp; -4 (severe aplastic anemia)</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TCRαβ-depleted hematopoietic cell transplantation</intervention_name>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS</intervention_name>
    <description>Immunogenetic depletion of TCRαβ cells</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A. Disease inclusions

          1. Hematologic malignancy:

               -  Acute lymphoblastic leukemia including induction failure, CR1 (Ph+, t(4:11),
                  hypodiploid and other very high risk features), ≥ CR2, infant ALL with MLL or
                  other unfavorable features

               -  Acute myeloid leukemia excluding CR1 with t(8:21), inv(16), t(15:17), and Down
                  syndrome

               -  Myelodysplastic syndrome: RCC with -7 or RCC in need of transfusion

               -  Chronic myeloid leukemia in AP

               -  Juvenile myelomonocytic leukemia

               -  Malignant lymphoma, NHL or HD, after failed autologous HSCT

               -  Other

          2. Non-hematologic malignancy

               -  Relapsed or refractory solid tumors including neuroblastoma, rhabdomyosarcoma and
                  so on

          3. Non-malignant hematologic disease

               -  Acquired severe and very severe aplastic anemia

               -  Fanconi anemia

               -  Paroxysmal nocturnal hemoglobinuria

               -  Congenital dyserythropoietic anemia

               -  Others

          4. Inherited or metabolic disease

               -  Hemophagocytic lymphohistiocytosis

               -  Malignant osteopetrosis

               -  Storage diseases

               -  Others B. Recipient inclusions

        1. Age &lt; 21 years 2. No HLA-identical stem cell donor available 3. Lansky-Play performance
        score &gt;60 4. No active infection at the time of transplantation

        Exclusion Criteria:

          1. HIV-infection

          2. Presence of active and serious infection

          3. Cardiac ejection fraction &lt;35% on echocardiography

          4. Severe pulmonary dysfunction (DLCO &lt;30%)

          5. Liver function abnormalities with bilirubin &gt;4mg/dL and elevation of transaminases &gt;
             400U/L

          6. Concurrent severe or uncontrolled medical disease

          7. Patients who are pregnant

          8. Patients unwilling or unable to comply with the protocol or unable to give informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Joon Im, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ho Joon Im, MD, PhD</last_name>
    <phone>82-2-3010-3371</phone>
    <email>hojim@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Joon Im, MD &amp; PhD</last_name>
      <phone>82-2-3010-3371</phone>
      <email>hojim@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Ho Joon Im, MD &amp; PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.mayoclinic.com/health/stem-cell-transplant/MY00089/METHOD=print</url>
    <description>Stem cell transplant</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/druginfo/meds/a692003.html</url>
    <description>fludarabine</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682080.html</url>
    <description>cyclophosphamide</description>
  </link>
  <link>
    <url>http://www.cancer.org/acs/groups/cid/documents/webcontent/003215-pdf.pdf</url>
    <description>stem cell transplantation</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/leukemia.html</url>
    <description>leukemia</description>
  </link>
  <reference>
    <citation>Park JA, Koh KN, Choi ES, Jang S, Kwon SW, Park CJ, Seo JJ, Im HJ. Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT. Bone Marrow Transplant. 2014 Feb;49(2):270-5. doi: 10.1038/bmt.2013.163. Epub 2013 Oct 21.</citation>
    <PMID>24141651</PMID>
  </reference>
  <reference>
    <citation>Im HJ, Koh KN, Choi ES, Jang S, Kwon SW, Park CJ, Chi HS, Seo JJ. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transplant. 2013 May;19(5):754-9. doi: 10.1016/j.bbmt.2013.01.023. Epub 2013 Feb 1.</citation>
    <PMID>23380343</PMID>
  </reference>
  <reference>
    <citation>Schumm M, Lang P, Bethge W, Faul C, Feuchtinger T, Pfeiffer M, Vogel W, Huppert V, Handgretinger R. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy. 2013 Oct;15(10):1253-8. doi: 10.1016/j.jcyt.2013.05.014.</citation>
    <PMID>23993299</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2013</study_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Ho Joon Im</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Children and adolescents</keyword>
  <keyword>Malignant disease</keyword>
  <keyword>Non-malignant disease</keyword>
  <keyword>TCRαβ depletion</keyword>
  <keyword>Haploidentical hematopoietic stem cell transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

